A method for therapy control of HPV16 positive carcinoma, an antibody for use in the corresponding diagnostic method as well as a test for performing the method. In particular, a serologic method for monitoring the development of the amount of antibodies in samples, which were taken from a patient before and after the treatment of a HPV16 positive carcinoma over a predetermined period of time. In addition, an immunologic test in the form of a kit, with which the method can be performed.

Provided herein are protein-based purification matrices and methods of use thereof to purify biologics and/or to remove contaminants from a composition. Methods of bringing two or more biologics in close proximity are also provided. The disclosed compositions and methods allow for faster, more efficient purification of a biologic compared to traditional affinity chromatography.

The subject of the invention is a bioreceptor molecule with the formula: R.sub.1-alkyl-C(0)NH—R.sub.2, wherein alkyl is linear or branched alkyl with 2 to 20 C atoms; R.sub.1 is selected from a group comprising thiol group (—SH); disulfide bridge; —S(O)-alkyl, wherein alkyl is linear or branched and contains 1-3 C atoms; thioether, wherein thioether contains 1-3 C atoms; thioacid; thionyl group; R.sub.2 is a peptide with a sequence selected from a group comprising SEQ ID NO 1-8. Another subject of the invention is the use of bioreceptor molecules according to the invention in electrochemical impedance spectroscopy for detecting the SARS-CoV-2 virus. The subject of the invention is also a sensor containing an electrode, whose surface is covered with a layer of metal, characterized in that this layer is modified by bioreceptor molecules according to the invention. Furthermore, the subject of the invention is the method of detecting the SARS-Cov-2 virus by means of electrochemical impedance spectroscopy, including the following steps: a. rinsing and drying of the sensor electrode covered with metal; b. modification of the sensor electrode surface with bioreceptor molecules; c. calibration of the measurement system; d. detection of SARS-Cov-2 virus in a sample by means of a measurement system by observation of impedance changes, characterized in that surface modification of the sensor electrode is carried out using bioreceptor molecules according to the invention, wherein the presence of the virus in the test sample is indicated by a change in impedance of at least 10% in absolute value against the baseline value.

The present disclosure is directed to antibodies binding to and neutralizing norovirus and methods for use thereof.

There is provided an influenza virus detection chip and a method for detecting influenza virus therewith. An influenza virus detection chip including: a graphene oxide film; a first pad disposed on one side of the graphene oxide film in a first direction; and a first electrode and a second electrode, connected to both ends of the graphene oxide film in a second direction perpendicular to the first direction, wherein a first monoclonal antibody with a fluorescent label is included in the first pad, and a second monoclonal antibody is included in the graphene oxide film, and wherein the fluorescent label includes a C═C—C═C conjugated double bond.

The embodiments disclose a method including providing impedimetric biosensor electrodes and circuits on a substrate, providing at least two different biopolymer materials on the conductive impedimetric biosensors electrodes and circuits, applying a predetermined electrical current to the impedimetric biosensor electrodes for establishing a baseline value, providing at least one biologic sample onto the impedimetric biosensors electrodes for detection of at least one disease microorganism, measuring the electrical current after contact with the at least one biologic sample for changes in the baseline value, recording changes in the electrical current measurements, analyzing the electrical current measurements for identifying predetermined detected disease microorganisms electrical current measurements changes, and determining the concentration of a detected disease microorganism.

A method of detecting an analyte in a fluid sample includes exposing a sensor including a substrate and a sensor medium on the substrate to the fluid sample for a period of time. The sensor medium includes a plurality of nanostructures and one or more of at least one agent selected from the group consisting of an antibody, an antigen receptor or an antigen immobilized upon at least a portion of the plurality of nanostructures. The at least one agent is an antibody or an antigen receptor if the analyte is an antigen and is an antigen if the analyte is an antibody. An electrolyte liquid having a known ionic strength which is less than the fluid sample is added over the sensor medium subsequent to exposing the sensor to the fluid and a variable providing a measure of change in at least one property of the sensor medium which is dependent upon the presence of the analyte is measured in presence of the electrolyte liquid.

Methods of detecting, predicting severity of, and/or predicting treatment response to respiratory virus infection in a sample obtained from a subject. The methods include assaying a methylation state of a marker in a sample obtained from a subject and identifying the subject as having respiratory virus infection, a likelihood of severe outcomes of respiratory infection, and/or a likelihood of treatment response depending on the methylation state of the marker. The markers can include bases (DMP) in differentially methylated regions (DMR) as provided herein.

A detection method and sensors are provided for the rapid detection of chemicals, biological and non-biological, and a wide range of viruses using magnetic tunnel junction-based molecular spintronics devices (MTJMSD) that produce unique magnetic resonance signals before and after interacting with target chemical, biochemical, viral, and other molecular agents.

The invention enables efficient, rapid, and sensitive enumeration of living cells by detecting microscopic colonies derived from in situ cell division using large area imaging. Microbial enumeration tests based on the invention address an important problem in clinical and industrial microbiology—the long time needed for detection in traditional tests—while retaining key advantages of the traditional methods based on microbial culture. Embodiments of the invention include non-destructive aseptic methods for detecting cellular microcolonies without labeling reagents. These methods allow for the generation of pure cultures which can be used for microbial identification and determination of antimicrobial resistance.